



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 15/54, 9/10, 5/10	A1	(11) International Publication Number: WO 94/21799 (43) International Publication Date: 29 September 1994 (29.09.94)
<p>(21) International Application Number: PCT/AU94/00126</p> <p>(22) International Filing Date: 15 March 1994 (15.03.94)</p> <p>(30) Priority Data: PL 7854 16 March 1993 (16.03.93) AU</p> <p>(71) Applicant: AUSTIN RESEARCH INSTITUTE [AU/AU]; Kroe- nheimer Building, Austin Hospital, Studley Road, Heidel- berg, VIC 3084 (AU).</p> <p>(72) Inventors: SANDRIN, Mauro, S.; 211 Barkly Street, Brunswick, VIC 3056 (AU). MCKENZIE, Ian, F., C.; 359 Brunswick Road, West Brunswick, VIC 3055 (AU).</p> <p>(74) Agents: STEARNE, Peter, Andrew et al.; Davies Collison Cave, Level 10, 10 Barrack Street, Sydney, NSW 2000 (AU).</p>		<p>(81) Designated States: AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: USE OF PORCINE GAL α(1,3) GALACTOSYL TRANSFERASE IN XENOGRAFT THERAPIES</p>		
<p>(57) Abstract</p> <p>DNA sequences encoding a porcine Galα(1,3) galactosyl transferase and clones containing such sequences are provided. The porcine Galα(1,3) galactosyl transferase produces the Galα(1,3) Gal epitope on the surfaces of porcine cells. This epitope is recognized by human anti-Galα(1,3) Gal antibodies which are responsible for hyperacute rejection of xenotransplanted pig cells, tissues and organs. Methods of reducing such hyperacute rejection are also provided.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

5 Use of Porcine Gal α (1,3) galactosyl transferase in xenograft therapies

 This invention relates to xenotransplantation
(transplantation across species) and is particularly
concerned with methods of alleviating xenotransplant
10 rejection, maintenance of xenotransplanted tissue in an
animal, nucleotide sequences useful in xenotransplant
therapies, rejection resistant transgenic organs, and
transgenic animals whose tissues are rejection-resistant
on xenotransplantation.

15 The current shortage of tissues for human
transplantation has led to recent close examination of
xenografts as a possible source of organs. However, when
tissues from non human-species are grafted to humans,
hyperacute rejection occurs due to the existence of
20 natural antibodies in human serum which react with
antigens present in these species, with rejection
occurring within 10-15 minutes of transplantation. This
phenomenon depends, in general, on the presence of some
or all of antibody, complement, neutrophils, platelets
25 and other mediators of inflammation. In transplantation
of vascularized organs between "discordant" species
(those in which natural antibodies occur) the first cells
to encounter natural antibodies are the endothelial cells

lining the blood vessels and it is likely that activation of these cells is induced by antibody binding to xenoantigens or other factors, leading to hyperacute rejection.

5 There is considerable uncertainty in the art concerning the nature of possible target xenoantigens on xenograft tissues. Platt et al (Transplantation 50:817-822,1990) and Yang et al (Transplant. Proc. 24:593-594, 1992) have identified a triad of
10 glycoproteins of varying molecular weights as the major targets on the surface of pig endothelial cells. Other investigators (Holgersson et al, Transplant Proc 24:605-608, 1992) indicate glycolipids as key xenoantigens.

15 We have now found that xenograft rejection, particularly in the context of pig tissue, is associated with antibodies reactive with galactose in an $\alpha(1,3)$ linkage with galactose, (the $\text{Gal}\alpha(1,3)\text{Gal}$ epitope) Modulating the interaction between antibodies reactive
20 with the $\text{Gal}\alpha(1,3)\text{Gal}$ epitope of xenotransplant tissue effects rejection.

 In accordance with the first aspect of this invention, there is provided a method of inhibiting xenotransplant rejection in an animal patient, comprising
25 administering to the patient an effective amount of an antagonist of antibody binding to xenotransplant antigens having galactose in an $\alpha(1,3)$ linkage with galactose.

Another aspect of this invention relates to the maintenance of xenograft tissue in an animal, which comprises administering to the animal a graft rejection effective amount of an antagonist to antibodies which
5 bind to the xenograft antigen epitope Gal α (1,3)Gal.

In another aspect of this invention there is provided a method of inhibiting the binding of antibodies to the Gal α (1,3)Gal epitope which comprises modulating the interaction between the antibodies and the epitope
10 with an antagonist which blocks the binding of the antibodies to the Gal α (1,3)Gal epitope.

Preferably the xenograft recipient is a human. Age is not a determining factor for xenograft transplantation although transplants in the elderly over 75 years would
15 normally not be carried out. The invention is directed particularly to human transplantation with xenograft tissue.

Xenografted tissue is preferably of pig origin. Tissues from other mammals are also contemplated for use
20 in this invention. Preferably the xenotransplanted tissue is in the form of an organ, for example, kidney, heart, lung or liver. Xenotransplant tissue may also be in the form of parts of organs, cell clusters, glands and the like. Examples include lenses, pancreatic islet
25 cells, skin and corneal tissue. The nature of the xenotransplanted tissue is not of itself critical as any xenotransplanted tissue which expresses antigens having

Gal α (1,3)Gal epitopes may be utilized in accordance with this invention.

The binding of antibody to the Gal α (1,3)Gal epitope expressed on xenotransplanted tissue provokes rejection of the tissue by humoral as well as cell-mediated immune effects leading to tissue rejection in a very short time scale, such as less than one hour. Antagonists which antagonize the binding of antibodies to the Gal α (1,3)Gal epitope block antibody binding and therefore inhibit xenotransplant rejection. Because antibody binding is blocked, immune responses which give rise to tissue rejection are prevented.

In accordance with a further aspect of this invention, there is provided an antagonist which modulates the interaction of antibodies directed against Gal α (1,3)Gal.

Any antagonist capable of modulating the interaction between antibodies directed to the Gal α (1,3)Gal linkage may be utilized in this invention. By reference to modulation, is meant blockage of antibody binding or decrease in affinity reactivity of antibodies for the Gal α (1,3)Gal epitope. Various mechanisms may be associated with the blockage of antibody binding or decreased affinity of antibodies for their respective epitope. These include binding or association with the antibody reactive site and change of conformation of the antibody reactive site, such as by binding to residues associated with, adjacent to, or distanced from the

active site, which effect the conformation of the active site such that it is incapable of binding the Gal α (1,3)Gal epitope or binds the epitope with reduced affinity. For example, in accordance with techniques well known in the art (see, for example, Coligan, et al., eds. Current Protocols In Immunology, John Wiley & Sons, New York, 1992; Harlow and Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988; and Liddell and Cryer, A Practical Guide To Monoclonal Antibodies, John Wiley & Sons, Chichester, West Sussex, England, 1991), such a change of the conformation of the antibody reactive site can be achieved through the use of an anti-idiotypic antibody raised against the natural antibody or fragments thereof. As is also well known in the art, these anti-idiotypic antibodies may be modified to enhance their clinical usefulness, for example by enzymatic techniques such as preparing Fab' fragments, or by recombinant techniques such as preparing chimeric, humanized, or single chain antibodies.

This invention is not limited to any specific antagonist and any antagonist which is non-toxic and which modulates the interaction between antibodies specific for the Gala(1,3)Gal epitope may be used in this invention. Suitable examples of antagonists include D-galactose and melibiose, stachyose and methyl- α -D-galactopyranoside, D-galactosamine and derivatives thereof. The term derivatives encompasses, for example, any alkyl, alkoxy, alkylkoxy, aralkyl amine,

hydroxyl, nitro, heterocycle, sulphate and/or cycloalkyl substituents whether taken alone or in combination, which derivatives have antagonist activities. This may be assessed according to methods as herein described.

5 Carbohydrate polymers containing one or more of the aforesaid carbohydrate moieties or derivatives may also be utilized in this invention.

The amount of antagonists which is effective to modulate interaction between antibodies reactive with
10 Gal α (1,3)Gal epitopes will vary depending upon a number of factors. These include the nature of the animal being treated, the nature of species of the transplanted tissue, the physical condition of the transplant recipient (age, weight, sex and health) and the like. In
15 respect of human transplant recipients of tissue, for example from pigs, the amount of antagonists administered will generally depend upon the judgement of a consulting physician. As an example, a graft rejection effective amount of an antagonist in human subjects may be in the
20 order of from 0.01mg to 1000gm per dose, more preferably 10mg to 500mg, more preferably 50mg to 300mg, and still more preferably 50mg to 200mg per dose.

The schedule of administration of antagonists to inhibit rejection and maintain xenografts will depend
25 upon varying factors as mentioned above. Varying dosage regimes may be contemplated, such as daily, weekly, monthly or the like.

The mode of administration of antagonists and dosage forms thereof are not critical to this invention. Antagonists may be administered parenterally (intravenous, intramuscular or intraorgan injection),
5 orally, transdermally, or by vaginal or anal routes, or by other routes of administration, as are well known in the art. Antagonists may be in solid or liquid form and would generally include pharmaceutically acceptable or veterinarily acceptable excipients and/or carriers.
10 Examples of dosage forms which may be used in this invention are those well known in the art as mentioned previously such as described in Remington's Pharmaceutical Sciences (Mack Publishing Company, 10th Edition, which is incorporated herein by reference).

15 In still another aspect of this invention, there is provided nucleotide sequences encoding $\alpha(1,3)$ galactosyl transferase and mutants thereof. Preferably, the nucleotide sequence encodes pig $\alpha(1,3)$ galactosyl transferase.

20 Nucleotide sequences may be in the form of DNA, RNA or mixtures thereof. Nucleotide sequences or isolated nucleic acids may be inserted into replicating DNA, RNA or DNA/RNA vectors as are well known in the art, such as plasmids, viral vectors, and the like (Sambrook et al,
25 Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY, Second Edition 1989).

Nucleotide sequences encoding $\alpha(1,3)$ galactosyl transferase may include promoters, enhancers and other

regulatory sequences necessary for expression, transcription and translation. Vectors encoding such sequences may include restriction enzyme sites for the insertion of additional genes and/or selection markers, as well as elements necessary for propagation and maintenance of vectors within cells.

Mutants of nucleotide sequences encoding $\alpha(1,3)$ galactosyl transferase are particularly preferred as they may be used in homologous recombination techniques as are well known in the art (Capecchi M R, Altering the Genome by Homologous Recombination, Science 244:1288-1292, 1989; Merlino G T, Transgenic Animals in Biomedical research, FASEB J 5:2996-3001, 1991; Cosgrove et al, Mice Lacking MHC Class II Molecules, Cell 66:1051-1066, 1991; Zijlstra et al, Germ-line Transmission of a disrupted B2-microglobulin gene produced by homologous recombination in embryonic stem cells, Nature 342:435, 1989) for the inactivation of wild type $\alpha(1,3)$ galactosyl transferase genes.

Mutant $\alpha(1,3)$ galactosyl transferase nucleotide sequences include nucleotide deletions, insertions, substitutions and additions to wild type $\alpha(1,3)$ galactosyl transferase such that the resultant mutant does not encode a functional galactosyl transferase. These nucleotide sequences may be utilized in homologous recombination techniques. In such techniques, mutant sequences are recombined with wild type genomic sequences in stem cells, ova or newly fertilized cells comprising

from 1 to about 500 cells. Nucleotide sequences utilized in homologous recombination may be in the form of isolated nucleic acids sequences or in the context of vectors. Recombination is a random event and on
5 recombination, destruction of the functional gene takes place.

Transgenic animals produced by homologous recombination and other such techniques to destroy wild type gene function are included within this invention, as
10 are organs derived therefrom. By way of example, transgenic pigs may be produced utilizing homologous recombination techniques to produce a transgenic animal having non-functional $\alpha(1-3)$ galactosyl transferase genomic sequences. Tissues derived from such transgenic
15 animals may then be utilized in xenotransplantation into human patients with the avoidance of immune reaction between circulating human antibodies reactive with $\text{Gal}\alpha(1-3)\text{Gal}$ epitopes. Such transplants are contemplated to be well tolerated by transplant recipients. Whilst
20 transplanted tissue may comprise other antigens which provoke immune reaction beyond those associated with $\text{Gal}\alpha(1-3)\text{Gal}$ epitopes, removing the major source of the immune reaction with such transplanted tissues should lead to xenotransplants being relatively well tolerated
25 in conjunction with standard rejection therapy (treatment with immune suppressants such as cyclosporin).

This invention will now be described with reference to the following non-limiting Figures and Examples.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: Figure 1A shows titer of pooled human serum before and after absorption. Titer obtained by hemagglutination on RBC (hatched bars) and rosetting assay on PBL (open bars) and spleen cells (solid bars). Absorption studies demonstrated that the same xeno antigens were present on all of these tissues (Figure 1 and Figure 2), as absorption with RBC, spleen cells or PBL, removed reactivity for the other cells (Figure 1A and Figure 2). Absorption of the serum pool with EC, while removing all of the EC reactive antibodies (Figure 2A), completely removed all PBL reactive antibodies and almost all the RBC hemagglutinating antibodies (titer fell from 1/128 to 1/2) (Figure 1A). Absorption with RBC removed 75% (Figure 2B) and spleen cells all (Figure 2C) of the EC reactive antibodies shown by flow cytometry. Thus, common epitopes are present on pig red cells, PBL, spleen and endothelial cells. Serum absorbed with EC was not tested on PBL or spleen cells. Figure 1B -- see Figure 3.

Figure 2: Testing of pig EC with pooled human serum before and after absorption. In each panel EC tested with absorbed serum (dotted line) or non absorbed serum (solid line). Serum absorbed with EC (panel A), RBC (panel B) or spleen cells (panel C). Binding of human antibody was detected using sheep anti-human IgM and analysis by flow cytometry.

Figure 3: Hemagglutination titer of treated and untreated human serum. Untreated human serum (A); protein-A non binding immunoglobulin (B); protein-A eluted immunoglobulin (C); serum treated with 2-mercaptoethanol (D). Figure 1B shows the same data with the addition of data obtained using a high molecular weight immunoglobulin fraction. Figure 1B: Untreated human serum (A); protein-A non binding immunoglobulin (B); high molecular weight fraction (C); protein-A eluted immunoglobulin (D); serum treated with 2-mercaptoethanol (E).

Figure 4: Carbohydrate inhibition of hemagglutination of normal human serum. Human serum was titered in the presence of 300mM solutions of carbohydrates.

Figure 5: Concentration of carbohydrate giving 50% inhibition of hemagglutination titer of normal human serum. Only carbohydrates inhibiting hemagglutination in Figure 4 were used in this experiment, with glucose and methyl- β -galactopyranoside as negative controls.

Figure 6: Hemagglutination titer of human serum on pig RBC pre and post absorption on a melibiose column. Human serum was absorbed with equal volumes of melibiose-sepharose (solid bars) or sepharose (open bars), a number of times as indicated in the figure axis.

Figure 7: Southern blot of pig genomic DNA probed with the cDNA insert of clone pPGT-4.

BRIEF DESCRIPTION OF THE SEQUENCE LISTINGS

SEQ ID NO:1 Partial nucleotide and predicted amino acid sequence of the pig Gal α (1,3) transferase.

5 SEQ ID NO:2 Complete nucleotide and predicted amino acid sequence of the pig Gal α (1,3) transferase.

SEQ ID NO:3 Nucleotide sequence for PCR primer α GT-1.

SEQ ID NO:4 Nucleotide sequence for PCR primer α GT-2.

10 With regard to SEQ ID NOS:1-2, it should be noted that the present invention is not limited to the specific sequences shown, but, in addition to the mutations discussed above, also includes changes that are found as naturally occurring allelic variants of the porcine Gal
15 α (1,3) galactosyl transferase gene, as well as nucleic acid mutations which do not change the amino acid sequences set forth in these sequences, e.g., third nucleotide changes in degenerate codons.

EXAMPLE 120 Materials and Methods

Cells. Pig cells and tissues were obtained from an abattoir from freshly slaughtered animals. Whole blood was centrifuged at 800g, and erythrocytes (RBC) obtained and were washed three times in phosphate buffered saline
25 (PBS); pig peripheral blood lymphocytes (PBL) were isolated by density gradient centrifugation using ISOPAQUE FICOLL (Vaughan et al, (1983) Transplantation 36:446-450). Pig splenocytes were obtained from whole

spleen by teasing tissue through a sieve to give a single cell suspension. Endothelial cell (EC) cultures were established after treatment of sterile pig aorta with Collagenase Type 4 (Worthington Biochemical Corporation, New Jersey) and the isolated cells were grown in Dulbecco's modified Eagles medium (DMEM) (ICN Biomedicals Australasia Pty Ltd, Seven Hills, NSW) on gelatin coated plates at 37°C. The endothelial origin of EC cultures was verified using rabbit anti human von Willebrand factor antibody (Dako A/S, Copenhagen) and indirect immunofluorescence. COS cells used were maintained in fully supplemented DMEM medium.

Antibodies. Human serum was obtained from a panel of normal volunteers, heat inactivated and pooled before use. The mAb HuLy-m3 (CD48), was used as a negative control (Vaughan Supra). Equal volumes of human serum and 5 to 200mM 2-mercaptoethanol were incubated at 37°C for one hour to destroy IgM.

Absorptions. Pooled serum was absorbed with equal volumes of washed, packed cells for 15 minutes at 37°C, for 15 minutes at 4°C, serum obtained and the procedure repeated three times. For the absorption with melibiose-agarose (Sigma, St Louis, MO) and sepharose (Pharmacia LKB Biotechnology, Uppsala, Sweden), equal volumes packed beads and serum were incubated at 37°C for 16 hours, the beads removed by centrifugation, and the absorption repeated several times.

Serological Assays. a) Hemagglutination: 50 μ l of 0.1% pig RBC were added to 50 μ l of human serum in 96 well plates, incubated at 37°C for 30 minutes, room temperature for 30 minutes and on ice for 60 minutes prior to both macroscopic and microscopic evaluation of hemagglutination; b) Rosetting: Sheep anti human IgG was coupled to sheep RBC with chromic chloride and used in a rosetting assay (Parish et al (1978) J Immunol. Methods 20:173-183); c) Cytofluorographic analysis was performed on FACScan (Becton Dickinson, San Jose, CA) (Vaughan et al (1991) Immunogenetics 33:113-117); d) Indirect immunofluorescence was performed on cell monolayers in 6 well tissue culture plates using fluoresceinated sheep anti human IgM or IgG (Silenus Laboratories Pty Ltd, Hawthorn, Victoria, Australia) (Vaughan Supra).

Sugar Inhibitions. Two types of sugar inhibition assays were performed: a) 50 μ l of sugars (300mM in PBS) were added to 50 μ l of doubling dilutions of human serum in 96 well plates, incubated overnight at 46°C and then 50 μ l of 0.1% pig RBC added and the hemagglutination assay performed; b) Human serum, diluted in PBS at one dilution less than that of the 50% hemagglutination titer, was added to 50 μ l of doubling dilutions of sugars (starting at 300mM) and incubated overnight at 4°C, after which 50 μ l of 0.1% pig RBC was added and the hemagglutination assay performed.

Murine Gal α (1-3) Transferase cDNA construct. A cDNA clone, encoding the mouse α (1,3)galactosyl

transferase was produced using the published sequence of this transferase (Larsen et al (1989) J Biol. Chem 264:14290-14297) and the polymerase chain reaction (PCR) technique. Briefly two oligonucleotides were synthesized; α GT-1 (5'-GAATTCAAGC TTATGATCAC TATGCTTCAA G-3') which is the sense oligonucleotide encoding the first six amino acids of the mature α GT and contains a HindIII restriction site, and α GT-2 (5'-GAATTCCTGC AGTCAGACAT TATTCTAAC-3') which is the anti-sense oligonucleotide encoding the last 5 amino acids of the mature α GT and the in phase termination codon and contains a PstI restriction site. This oligonucleotide pair was used to amplify a 1185 bp fragment from a C57BL/6 spleen cell cDNA library (Sandrin et al (1992) J Immunol. 194:1636-1641). The 1185 bp fragment was purified from a Low Gelling point agarose gel, digested with HindIII and PstI (Pharmacia) restriction endonucleases, and directionally cloned into HindIII/PstI digested CDM8 vector (Seed B (1987) Nature 329:840 842) using T4 ligase (Pharmacia). The product of the ligation was used to transform MC1061/p3, and DNA prepared from resultant colonies for further examination. One plasmid (p α GT-3) having the 1185 bp fragment was selected for further studies. Plasmid DNA was prepared, sequenced to confirm the correct DNA sequence, and used for COS cells transfection experiments using DEAE/Dextran (Vaughan et al (1991) Immunogenetics 33: 113-117; Sandrin et al

(1992) J Immunol. 194:1636-1641, Seed B (1987) Nature 329:840-842).

EXAMPLE 2

Human Anti-pig Antibodies Detect

5 Epitopes Present on Different Cells

To establish that human serum contains antibodies to pig cells which are predominantly of the IgM class, a pool of human serum was made (from 10 donors) and found to contain antibodies which reacted with pig red cells (by hemagglutination); pig lymphocytes (rosetting assay and flow cytometry); pig spleen cells (rosetting); and pig endothelial cells (flow cytometry) (Figures 1 and 2). Absorption studies demonstrated that the same xeno antigens were present on all of these tissues (Figure 1 and Figure 2), as absorption with RBC, spleen cells or PBL, removed reactivity for the other cells (Figure 1A and Figure 2). Absorption of the serum pool with EC, while removing all of the EC reactive antibodies (Figure 2a), completely removed all PBL reactive antibodies and almost all the RBC hemagglutinating antibodies (titer fell from 1/128 to 1/2) (Figure 1A). Absorption with RBC removed 75% (Figure 2B) and spleen cells all (Figure 2C) of the EC reactive antibodies shown by flow cytometry. Thus, common epitopes are present on pig red cells, PBL, spleen and endothelial cells.

Most of the activity in the serum pool was due to IgM rather than IgG antibodies as indicated by the inability of a protein A-sepharose column, which does not

bind IgM, to alter the titer of the serum after passage through the column (Figure 3), and IgG antibodies eluted from the protein A-sepharose column reacted only weakly with RBC (Figure 3). Furthermore, treatment of the serum with 2-mercaptoethanol, which destroys IgM but leaves IgG intact, led to a complete loss of antibody activity (Figure 3). When the serum was fractionated by SEPHACRYL gel chromatography, the high molecular weight fractions (IgM) were reactive with RBC, whereas the low molecular weight fractions (IgG) were not (data not shown). Thus the different pig cells carry similar epitopes, all reacted with IgM antibodies and in our assays there was little IgG activity found in the human serum for pig cells.

15

EXAMPLE 3Human Anti-pig Antibodies React Predominantly
With Terminal Galactose Residues

The ability of different carbohydrates to inhibit the hemagglutination reaction (Figure 4) was examined. Of the sugars tested, inhibition as measured by a decrease in titer, was observed with 300mM galactose, methyl- α -D-galactopyranoside, melibiose and stachyose, all of which decreased the titer of the serum pool by 75% (Figure 4); and with 300mM D-galactosamine, for which a 50% decrease in titer was observed (Figure 4). None of the other monosaccharides tested (listed in the figure legend) had any effect on hemagglutination titer (Figure 4). These studies demonstrated that galactose is the

part of the epitope, as both melibiose and stachyose have terminal galactose residues. It is of interest to note the difference in the ability of galactose in the α (methyl- α -D-galactopyranoside, melibiose and stachyose) but not β (methyl- β -D-galactopyranoside) configuration to inhibit the serum.

The relative avidity of the antibodies for the sugars which inhibited agglutination was estimated from the concentration of sugar giving 50% inhibition of the agglutination titer (Figure 5). Both D-galactose and melibiose achieved this inhibition at <1.5mM, stachyose and methyl- α -D-galactopyranoside at 4.7mM and D-galactosamine at 18.7mM (Figure 5). By contrast, D-glucose and methyl- β -D-galactopyranoside had no effect even at 300mM concentration. Thus D-galactose is an important part of the epitope, as it is a potent inhibitor of the xenoantibodies at low concentration (<1.1 5mM); the ability of methyl- α -D-galactopyranoside to inhibit agglutination at low concentrations (<1.15mM), compared with the failure of methyl- β -D-galactopyranoside (300mM) to inhibit, demonstrates that the galactose residue (which is likely to be a terminal sugar) is in an α -linkage rather than a β -linkage with the subterminal residue. The results obtained with melibiose (Gal α (1,6)Glc) and stachyose (Gal α (1,6)Gal α (1,6)Glc β (1,2)Fru), which have α -linked terminal galactose residues, are in accord with this

conclusion. The inhibition of hemagglutination observed with galactosamine, which has an additional amine side chain on galactose, (50% inhibition of titer at 18.7mM) could be due to a second carbohydrate involved in the epitope, or a lower affinity of the xenoantibodies for this sugar.

To further examine the reaction with galactose, the serum pool was absorbed four times with equal volumes of packed melibiose sepharose or with sepharose as the control (Figure 6), one absorption with melibiose-sepharose decreased the titer of the antibody from 1/32 to 1/4, and two sequential absorptions decreased the titer further to 1/2 (Figure 6). This absorption was specific for melibiose, as using sepharose beads had no effect (Figure 6). Thus the majority of the antibody (=94%) reactive with xenoantigens reacts with galactose in an α -linkage.

EXAMPLE 4

Human Anti-Pig Antibodies React with COS Cells

After Transfection with $\alpha(1,3)$ Galactosyl Transferase

The cDNA coding for the $\alpha(1,3)$ galactosyl transferase which transfers a terminal galactose residue with an $\alpha(1,3)$ linkage to a subterminal galactose has been cloned for both mouse (Larsen et al (1989) J Biol Chem 264:14290-14297) and ox (Joziassse et al (1989) J Biol Chem 264:14290-14297). Using this data we used transfection experiments to determine the role of the Gal $\alpha(1,3)$ Gal epitope in isolation of others. The mouse

transferase was isolated from a cDNA library using the PCR technique, and the PCR product was directionally cloned into the CDM8 vector for expression studies in COS cells. The cDNA insert was sequenced in both directions and shown to be identical to the published nucleotide sequence (Larsen et al (1989) J Biol Chem 264:14290-14297). COS cells, derived from Old World Monkeys, were chosen as they do not react with human serum nor with the IB-4 lectin (which is specific for the Gal α (1,3)Gal epitope) (Table 1). After transfection of COS cells with the α (1,3)galactosyl transferase, the Gal α (1,3)Gal epitope was detected on the cell surface by binding of the IB-4 lectin (Table 1); these cells were also strongly reactive with the serum pool. Absorbing the human sera with pig RBC removed the reactivity for Gal α (1,3)Gal⁺COS cells, (Table 1). Passage of the serum over a protein-A sepharose column had no effect on the reactivity of the serum for Gal α (1,3)Gal⁺COS cells, when using an FITC conjugated sheep anti-human IgM as the second antibody (this was reflected in the same number of reactive cells, the intensity of staining and the titer of the serum (Table 1)). In contrast to this, eluted antibodies reacted only weakly with the Gal α (1,3)Gal⁺COS cells, and this reaction was only observed when using FITC conjugated sheep anti-human IgG or FITC conjugated sheep anti-human Ig, but not FITC conjugated sheep anti human IgM (Table 1). Thus human serum has IgM antibodies to the Gal α (1,3)Gal epitope which was expressed on

Gal α (1,3)Gal⁺COS cells. The reaction of the serum with Gal α (1,3)Gal⁺COS cells is specific and not due to the transfection procedure as CD48⁺ COS cells were not reactive with either the serum nor the IB-4 lectin (Table 1). Furthermore, the reactivity for both pig RBC (as detected by hemagglutination) and EC (as detected by FACS analysis) could be removed by absorption with Gal α (1,3)Gal⁺COS cells but not untransfected COS cells. Thus human serum pool contains IgM antibodies reactive with the Gal α (1,3)Gal epitope.

The level of antibodies in human serum reactive with the Gal α (1,3)Gal epitope can be used to determine the propensity of a patient to hyperacutely reject a porcine xenotransplant. In addition, the level of such antibodies can be used to determine the amount of antibody antagonist that should be administered to a patient prior to such xenotransplantation.

The level of these antibodies can be effectively determined using the transfected and untransfected COS cells described above as matched Gal α (1,3)Gal⁺ and Gal α (1,3)Gal⁻ absorbants, followed by a measurement of the reactivity of the absorbed serum for pig RBC and/or EC. Higher levels of serum antibody will result in a larger difference in reactivity of the serum absorbed against the Gal α (1,3)Gal⁺ absorbant versus that absorbed against the Gal α (1,3)Gal⁻ absorbant. Cells from other species, e.g., human cells, can be used in such an assay. Also, rather than using a DNA sequence encoding the murine

transferase, a DNA sequence encoding the porcine transferase (see Example 5) can be used. Such a porcine transferase is preferred since there may be differences in the action of the murine and porcine transferases, e.g., altered sensitivity to the macromolecular environment of the galactose substrate of the enzyme, and for a porcine xenotransplantation, it is the level of antibodies against the Gal α (1,3)Gal epitope in the porcine macromolecular environment that is of interest.

In addition to the foregoing, the transfected Gal α (1,3)Gal⁺ cells described above can also be used as absorbants to remove anti-Gal α (1,3)Gal antibodies from human serum, e.g., by binding such cells to a solid support and passing the serum over the immobilized cells.

15

EXAMPLE 5

Cloning of Porcine α (1,3) Galactosyl Transferase

Utilizing the murine cDNA clone for the α (1,3) galactosyl transferase as a hybridization probe we have cloned the pig α (1,3) galactosyl transferase from a λ GT11 pig spleen cDNA library (Clontech Laboratories, Palo Alto, CA) according to standard methods as described in Sambrook et al (supra). This clone, pPGT-4, has been deposited with the AGAL and assigned accession number N94/9030. SEQ ID NO:1 shows a partial nucleotide sequence and predicted amino acid sequence of pig Gal α (1,3) transferase as determined by sequencing of clone pPGT-4. The sequence shown is incomplete at the 5' end.

25

Utilizing the cDNA insert of the pPGT-4 clone as a hybridization probe we have also cloned the 5' end of the pig $\alpha(1,3)$ galactosyl transferase from a 5' STRECH pig liver cDNA library in λ gt10, according to standard methods as described in Sambrook et al (supra). The insert was obtained by the PCR technique using a λ oligonucleotide, and an oligonucleotide made to the pig sequence. This PCR product was subcloned into SmaI cut pBLUESCRIPT KS⁺. This clone, pPGT-2, has been deposited with the AGAL and assigned accession number N94/9029.

SEQ ID NO:2 shows a complete nucleotide sequence and predicted amino acid sequence of pig Gal $\alpha(1,3)$ transferase as determined by sequencing of clones pPGT-4 and pPGT-2. The pig transferase has high sequence homology with both the murine and bovine $\alpha(1,3)$ galactosyl transferase genes.

Both the partial and complete cDNA sequences of SEQ ID NOS:1-2 can be used in the xenotransplant therapies discussed above. For example, using techniques well known in the art, all or a part of any of the nucleotide sequences of SEQ ID NOS:1-2, when inserted into replicating DNA, RNA or DNA/RNA vectors, can be used to reduce the expression of the Gal $\alpha(1,3)$ transferase in porcine cells by directing the expression of anti-sense RNAs in transgenic cells or animals. See, for example, Biotechniques, 6(10):958-976, 1988.

In addition, as illustrated in the following example, the sequences of SEQ ID NOS:1-2 can be used as hybridization probes for the characterization and isolation of genomic clones encoding the porcine Gal α (1,3) transferase. Mutants of the genomic nucleotide sequence, in turn, can be used in homologous recombination techniques of the types described above so that destruction of the functional gene takes place in porcine cells.

EXAMPLE 6

Characterization and Isolation of the Porcine Gene Encoding α (1,3) Galactosyl Transferase

Genomic DNA prepared from pig spleen tissue was digested with EcoR1, BamH1, Pst1, HindIII, Kpn1 and BstEII, electrophoresed on a 0.8% agarose gel and transferred to a nylon filter, the final wash was at 65°C in 0.1x SSC, 0.1% SDS. As shown in Figure 7, the genomic Southern blot demonstrated a simple pattern suggesting that the gene exists as a single copy with a genomic size of ~25kb.

Utilizing the cDNA insert of the pPGT-4 clone as a hybridization probe, we have cloned the porcine α (1,3) galactosyl transferase gene from a pig genomic DNA EMBL library (Clontech Laboratories, Inc., Palo Alto, CA) according to standard methods as described in Sambrook et al (supra). This cloning has resulted in the isolation of two lambda phage clones, λ PGT-g1 and λ PGT-g5 that

contain different regions of the porcine transferase gene.

As discussed above, the gene for the $\alpha(1,3)$ galactosyl transferase can be used to effect targeted
5 destruction of the native gene for this enzyme using homologous recombination technology. In accordance with the conventional techniques used in this art, such gene knockout is performed using fragments obtained from genomic clones of the type provided by this example. The
10 gene destruction can be performed in somatic or stem cells (Capecchi, 1989, supra). Because such genetically engineered cells do not produce the $\text{Gal}\alpha(1,3)\text{Gal}$ epitope, they and their progeny are less likely to induce hyperacute rejection in humans and are thus suitable for
15 xenotransplantation into human patients.

EXAMPLE 7

Production of Anti-idiotypic Antibodies

Against Human Anti- $\text{Gal}\alpha(1,3)\text{Gal}$ Antibodies

Polyclonal anti-idiotypic antibodies against human
20 anti- $\text{Gal}\alpha(1,3)\text{Gal}$ antibodies are prepared following the procedures of Coligan, et al., 1992, supra; Harlow and Lane, 1988, supra; and Liddell and Cryer, 1991, supra. Human anti- $\text{Gal}\alpha(1,3)\text{Gal}$ antibodies are absorbed from pooled human serum onto immobilized melibiose (melibiose-
25 sepharose or melibiose-agarose) as described above in Example 3. The antibodies are eluted using standard methods, such as, high or low pH, high salt, and/or chaotropic agents. Fab' fragments are prepared following

dialysis into an appropriate buffer. The Fab' fragments are used to immunize rabbits, goats, or other suitable animals, along with conventional adjuvants.

5 The resulting polyclonal antisera are tested for their ability to change the conformation of the human antibody reactive site so as to reduce its affinity for the Gal α (1,3)Gal epitope. Those sera that produce such reduced affinity constitute the desired anti-idiotypic antibodies.

10 Monoclonal antibodies are produced using the same Fab' fragments as antigens to immunize appropriate strains of mice. Hybridomas are prepared by fusing spleen cells from such immunized mice with murine myeloma cells. Supernatants are tested for antibodies having the
15 ability to change the conformation of the human antibody reactive site so as to reduce its affinity for the Gal α (1,3)Gal epitope. Those antibodies that produce such reduced affinity constitute the desired monoclonal anti-idiotypic antibodies.

20 The finding that the majority of xenoreactive IgM is directed to the enzymatic product of the single transferase raises the possibility of producing transgenic pigs lacking the epitope, by targeted destruction of the α (1,3) galactosyl transferase genes
25 using homologous recombination technology. Such genetically modified pigs could be used for transplantation. The destruction of the gene is likely to have no deleterious effect on the pig - humans live

normally in its absence.

This invention has been described by way of example only and is in no way limited by the specific examples herewith.

5

DEPOSITS

Clones pPGT-4, pPGT-2, λPGT-g1, and λPGT-g5, discussed above, have been deposited with the Australian Government Analytical Laboratories, (AGAL), 1 Suakin Street, Pymble, N.S.W. 2073, Australia, and have been
10 assigned the designations N94/9030, N94/9029, N94/9027, and N94/9028, respectively. These deposits were made under the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for the Purposes of Patent Procedure (1977). These deposits were
15 made on March 11, 1994.

TABLE 1Serology On Transfected COS Cells

<u>Serum</u>	<u>Target</u>	<u>Reaction¹</u>
NHS	GT ⁺ COS	+++
NHS abs RBC	GT ⁺ COS	-
NHS Tx 2-ME	GT ⁺ COS	-
NHS abs Protein A	GT ⁺ COS	+++ ²
NHS Eluted Protein A	GT ⁺ COS	+ ³
CD48	GT ⁺ COS	-
NHS	CD48 ⁺ COS	-
CD48	CD48 ⁺ COS	+++
NHS	COS	-
CD48	COS	-
<hr/>		
IB4 ⁴	GT ⁺ COS	+++
IB4	CD48 ⁺ COS	-
IB4	COS	-

¹ Reactivity detected by indirect immunofluorescence using FITC conjugated sheep anti-human Ig or FITC conjugated sheep anti-mouse Ig unless otherwise stated.

² No difference in titer was observed when tested with FITC conjugated sheep anti-human IgM.

³ Reaction detected on protein A purified immunoglobulin using FITC conjugated sheep anti-human Ig or FITC conjugated sheep anti-human IgG, but not with FITC conjugated sheep anti-human IgM.

⁴ Reactivity detected using FITC conjugated IB4 lectin.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: The Austin Research Institute
- (ii) TITLE OF INVENTION: XENOTRANSPLANTATION THERAPIES
- (iii) NUMBER OF SEQUENCES: 4
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Peter A. Stearne
 - (B) STREET: Level 10, 10 Barrack Street
 - (C) CITY: Sydney
 - (D) STATE: New South Wales
 - (E) COUNTRY: Australia
 - (F) Postal Code 2001
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Peter A. Stearne
 - (C) REFERENCE/DOCKET NUMBER: 462552/pas
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 612 262 2611
 - (B) TELEFAX: 612 262 1080

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1353 base pairs

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Double

(D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA to mRNA

(A) DESCRIPTION: galactosyl transferase, 3'
clone

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Sus scrofa

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GTA	CCG	AGC	TCG	AAT	TCC	GCA	AGC	CAG	TCA	CCA	CAA	GCC	ATG	42
Val	Pro	Ser	Ser	Asn	Ser	Ala	Ser	Gln	Ser	Pro	Gln	Ala	Met	
			50					55					60	
ACT	GAC	CCA	TGT	TCC	CCC	AGA	CTG	TCG	TAC	CTT	AGC	AAA	GCC	84
Thr	Asp	Pro	Cys	Ser	Pro	Arg	Leu	Ser	Tyr	Leu	Ser	Lys	Ala	
			65					70						
ATC	CTG	ACT	CTA	TGT	TTT	GTC	ACC	AGG	AAA	CCC	CCA	GAG	GTC	126
Ile	Leu	Thr	Leu	Cys	Phe	Val	Thr	Arg	Lys	Pro	Pro	Glu	Val	
	75				80					85				
GTG	ACC	ATA	ACC	AGA	TGG	AAG	GCT	CCA	GTG	GTA	TGG	GAA	GGC	168
Val	Thr	Ile	Thr	Arg	Trp	Lys	Ala	Pro	Val	Val	Trp	Glu	Gly	
	90				95					100				
ACT	TAC	AAC	AGA	GCC	GTC	TTA	GAT	AAT	TAT	TAT	GCC	AAA	CAG	210
Thr	Tyr	Asn	Arg	Ala	Val	Leu	Asp	Asn	Tyr	Tyr	Ala	Lys	Gln	
		105					110					115		
AAA	ATT	ACC	GTG	GGC	TTG	ACG	GTT	TTT	GCT	GTC	GGA	AGA	TAC	252
Lys	Ile	Thr	Val	Gly	Leu	Thr	Val	Phe	Ala	Val	Gly	Arg	Tyr	
			120					125					130	
ATT	GAG	CAT	TAC	TTG	GAG	GAG	TTC	TTA	ATA	TCT	GCA	AAT	ACA	294
Ile	Glu	His	Tyr	Leu	Glu	Glu	Phe	Leu	Ile	Ser	Ala	Asn	Thr	
				135					140					
TAC	TTC	ATG	GTT	GGC	CAC	AAA	GTC	ATC	TTT	TAC	ATC	ATG	GTG	336
Tyr	Phe	Met	Val	Gly	His	Lys	Val	Ile	Phe	Tyr	Ile	Met	Val	
	145				150					155				
GAC	GAT	ATC	TCC	AGG	ATG	CCT	TTG	ATA	GAG	CTG	GGT	CCT	CTG	378
Asp	Asp	Ile	Ser	Arg	Met	Pro	Leu	Ile	Glu	Leu	Gly	Pro	Leu	
	160					165					170			
CGT	TCC	TTT	AAA	GTG	TTT	GAG	ATC	AAG	TCC	GAG	AAG	AGG	TGG	420
Arg	Ser	Phe	Lys	Val	Phe	Glu	Ile	Lys	Ser	Glu	Lys	Arg	Trp	
		175					180					185		
CAA	GAC	ATC	AGC	ATG	ATG	CGC	ATG	AAG	ACC	ATC	GGG	GAG	CAC	462
Gln	Asp	Ile	Ser	Met	Met	Arg	Met	Lys	Thr	Ile	Gly	Glu	His	
			190					195					200	
ATC	CTG	GCC	CAC	ATC	CAG	CAC	GAG	GTG	GAC	TTC	CTC	TTC	TGC	504
Ile	Leu	Ala	His	Ile	Gln	His	Glu	Val	Asp	Phe	Leu	Phe	Cys	
				205					210					

ATT Ile 215	GAC Asp Val	GTG Val Asp	GAT Asp Gln	CAG Gln Val	GTC Val 220	TTC Phe Gln	CAA Gln Asn	AAC Asn Asn	TTT Phe 225	GGG Gly Val	GTG Val Glu	GAG Glu 256	
ACC Thr 230	CTG Leu Gly	GGC Gln Ser	CAG Gln Val	TCG Ser Val	GTC Val 325	GCT Ala Gln	CTA Leu Gln	CAG Gln Ala	GCC Ala Trp	TGG Trp Tyr	TGG Trp Tyr	TAC Tyr Tyr	
AAG Lys 245	GCA Ala His	CAT His Pro	CCT Pro Asp	GAC Asp Glu	GAG Glu Phe	TTC Phe Thr	ACC Thr Tyr	TAC Tyr Glu	GAG Glu Arg	CGG Arg Pro	CCG Pro Lys	GAG Glu 255	
TCC Ser 260	GCA Ala Ala	GCC Ala Tyr	TAC Tyr Ile	ATT Ile Pro	CCG Pro Phe	TTT Phe Arg	CGC Arg Gln	CAG Gln Gly	GGG Gly Asp	GAT Asp Phe	TTT Phe Tyr	TAC Tyr Tyr	
CAC His 275	GCA Ala Ala	GCC Ala Ile	ATT Ile Leu	TTG Leu Gly	GGG Gly Gly	GGA Gly Thr	ACA Thr Pro	CCC Pro Thr	ACT Thr Gln	CAG Gln Val	GTT Val Leu	AAC Asn 280	
ATC Ile 285	ACT Thr Gln	CAG Gln Glu	GAG Glu Cys	TGC Cys Phe	TTC Phe Lys	AAG Lys Gly	GGA Gly Ile	ATC Ile Leu	CTC Leu Gln	CAG Gln Asp	GAC Asp Lys	GAA Glu 295	
AAT Asn 300	GAC Asp Ile	ATA Ile Glu	GAA Glu Ala	GCC Ala Glu	GAG Glu Trp	TGG Trp His	CAT His Asp	GAT Asp Glu	GAA Glu Ser	AGC Ser Gly	GGG Gly Leu	AAC Asn 310	
AAG Lys 315	TAT Tyr Phe	TTC Phe Leu	CTT Leu Leu	CTC Leu Asn	AAC Asn Lys	AAA Lys Pro	CCC Pro Thr	ACT Thr Lys	AAA Lys Ile	ATC Ile Leu	TTA Leu Ser	CCA Pro 325	
GAA Glu 330	TAC Tyr Cys	TGC Cys Trp	TGG Trp Asp	GAT Asp Tyr	TAT Tyr His	CAT His Ile	ATA Ile Gly	GGC Gly Met	ATG Met Ser	TCT Ser Val	GTG Val Asp	ATT Ile 340	
AGG Arg 345	ATT Ile Val	GTC Val Lys	AAG Lys Gly	GGG Gly Ala	GCT Ala Trp	TGG Trp Gln	CAG Gln Lys	AAA Lys Lys	AAA Lys Glu	GAG Glu Tyr	TAT Tyr Asn	TTG Leu 350	
GTT Val 355	AGA Arg Asn	AAT Asn Asn	AAC Asn Ile	ATC Ile Val	TGACTTTTAAA TTGTGCCAGC AGTTTTCTGA								969
ATTTGAAAGA GTATTACTCT GGCTACTTCC TCAGAGAAGT AGCACTTAAT													1019
TTTAACTTTT CAAAAAATAC TAACAAAATA CCAACACAGT AAGTACATAT													1069
TATTCTTCCT TGCAACTTTG AGCCTTGTC AATGGGAGAA TGACTCTGTA													1119
GTAATCAGAT GTAAATTCCC AATGATTTCT TATCTGCGGA ATTCCAGCTG													1169
AGCGCCGGTC CTACCATTAC CAGTTGGTCT GGTGTGCGACG ACTCCTGGAG													1219
CCCGTCAGTA TCGGCGGAAT TCGCGGCCGG GCGCCAATGC ATTGGGCCCA													1269

ATTCCGCCCT ATAGTGAGTC GTATTACAAT TCACTGGCCG TGTTTTACAA	1319
CCTCGTGA CT GGGAAAACCC TGGCCTTACC CAAC	1353

- (2) INFORMATION FOR SEQ ID NO:2:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1423 base pairs
 - (B) TYPE: Nucleic Acid
 - (C) STRANDEDNESS: Double
 - (D) TOPOLOGY: Linear
 - (ii) MOLECULE TYPE: cDNA to mRNA
 - (A) DESCRIPTION: galactosyl transferase,
full coding sequence
 - (iii) HYPOTHETICAL: No
 - (iv) ANTI-SENSE: No
 - (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Sus scrofa*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CGGGGGCCAT CCCCAGAGCGC ACCCAGCTTC TGCCGATCAG GAGAAAATA	49
ATG AAT GTC AAA GGA AGA GTG GTT CTG TCA ATG CTG CTT GTC Met Asn Val Lys Gly Arg Val Val Leu Ser Met Leu Leu Val	91
5 10	
TCA ACT GTA ATG GTT GTG TTT TGG GAA TAC ATC AAC AGA AAC Ser Thr Val Met Val Val Phe Trp Glu Tyr Ile Asn Arg Asn	133
15 20 25	
CCA GAA GTT GGC AGC AGT GCT CAG AGG GGC TGG TGG TTT CCG Pro Glu Val Gly Ser Ser Ala Gln Arg Gly Trp Trp Phe Pro	175
30 35 40	
AGC TGG TTT AAC AAT GGG ACT CAC AGT TAC CAC GAA GAA GAA Ser Trp Phe Asn Asn Gly Thr His Ser Tyr His Glu Glu Glu	217
45 50 55	
GAC GCT ATA GGC AAC GAA AAG GAA CAA AGA AAA GAA GAC AAC Asp Ala Ile Gly Asn Glu Lys Glu Gln Arg Lys Glu Asp Asn	259
60 65 70	
AGA GGA GAG CTT CCG CTA GTG GAC TGG TTT AAT CCT GAG AAA Arg Gly Glu Leu Pro Leu Val Asp Trp Phe Asn Pro Glu Lys	301
75 80	
CGC CCA GAG GTC GTG ACC ATA ACC AGA TGG AAG GCT CCA GTG Arg Pro Glu Val Val Thr Ile Thr Arg Trp Lys Ala Pro Val	343
85 90 95	
GTA TGG GAA GGC ACT TAC AAC AGA GCC GTC TTA GAT AAT TAT Val Trp Glu Gly Thr Tyr Asn Arg Ala Val Leu Asp Asn Tyr	385
100 105 110	
TAT GCC AAA CAG AAA ATT ACC GTG GGC TTG ACG GTT TTT GCT Tyr Ala Lys Gln Lys Ile Thr Val Gly Leu Thr Val Phe Ala	427
115 120 125	
GTC GGA AGA TAC ATT GAG CAT TAC TTG GAG GAG TTC TTA ATA Val Gly Arg Tyr Ile Glu His Tyr Leu Glu Glu Phe Leu Ile	469
130 135 140	
TCT GCA AAT ACA TAC TTC ATG GTT GGC CAC AAA GTC ATC TTT Ser Ala Asn Thr Tyr Phe Met Val Gly His Lys Val Ile Phe	511
145 150	
TAC ATC ATG GTG GAT GAT ATC TCC AGG ATG CCT TTG ATA GAG Tyr Ile Met Val Asp Asp Ile Ser Arg Met Pro Leu Ile Glu	553
155 160 165	

CTG Leu	GGT Gly	CCT Pro	CTG Leu	CGT Arg	TCC Ser	TTT Phe	AAA Lys	GTG Val	TTT Phe	GAG Glu	ATC Ile	AAG Lys	TCC Ser	595
170						175					180			
GAG Glu	AAG Lys	AGG Arg	TGG Trp	CAA Gln	GAC Asp	ATC Ile	AGC Ser	ATG Met	ATG Met	CGC Arg	ATG Met	AAG Lys	ACC Thr	637
		185					190					195		
ATC Ile	GGG Gly	GAG Glu	CAC His	ATC Ile	CTG Leu	GCC Ala	CAC His	ATC Ile	CAG Gln	CAC His	GAG Glu	GTG Val	GAC Asp	679
			200					205					210	
TTC Phe	CTC Leu	TTC Phe	TGC Cys	ATT Ile	GAC Asp	GTG Val	GAT Asp	CAG Gln	GTC Val	TTC Phe	CAA Gln	AAC Asn	AAC Asn	721
				215					220					
TTT Phe	GGG Gly	GTG Val	GAG Glu	ACC Thr	CTG Leu	GGC Gly	CAG Gln	TCG Ser	GTG Val	GCT Ala	CAG Gln	CTA Leu	CAG Gln	763
225					230					235				
GCC Ala	TGG Trp	TGG Trp	TAC Tyr	AAG Lys	GCA Ala	CAT His	CCT Pro	GAC Asp	GAG Glu	TTC Phe	ACC Thr	TAC Tyr	GAG Glu	805
	240					245					250			
AGG Arg	CGG Arg	AAG Lys	GAG Glu	TCC Ser	GCA Ala	GCC Ala	TAC Tyr	ATT Ile	CCG Pro	TTT Phe	GGC Gly	CAG Gln	GGG Gly	847
		255					260					265		
GAT Asp	TTT Phe	TAT Tyr	TAC Tyr	CAC His	GCA Ala	GCC Ala	ATT Ile	TTT Phe	GGG Gly	GGA Gly	ACA Thr	CCC Pro	ACT Thr	889
			270					275					280	
CAG Gln	GTT Val	CTA Leu	AAC Asn	ATC Ile	ACT Thr	CAG Gln	GAG Glu	TGC Cys	TTC Phe	AAG Lys	GGA Gly	ATC Ile	CTC Leu	931
				285					290					
CAG Gln	GAC Asp	AAG Lys	GAA Glu	AAT Asn	GAC Asp	ATA Ile	GAA Glu	GCC Ala	GAG Glu	TGG Trp	CAT His	GAT Asp	GAA Glu	973
295					300					305				
AGC Ser	CAT His	CTA Leu	AAC Asn	AAG Lys	TAT Tyr	TTC Phe	CTT Leu	CTC Leu	AAC Asn	AAA Lys	CCC Pro	ACT Thr	AAA Lys	1015
	310					315					320			
ATC Ile	TTA Leu	TCC Ser	CCA Pro	GAA Glu	TAC Tyr	TGC Cys	TGG Trp	GAT Asp	TAT Tyr	CAT His	ATA Ile	GGC Gly	ATG Met	1057
		325					330					335		
TCT Ser	GTG Val	GAT Asp	ATT Ile	AGG Arg	ATT Ile	GTC Val	AAG Lys	ATA Ile	GCT Ala	TGG Trp	CAG Gln	AAA Lys	AAA Lys	1099
			340				345						350	
GAG Glu	TAT Tyr	AAT Asn	TTG Leu	GTT Val	AGA Arg	AAT Asn	AAC Asn	ATC Ile	TGACTTTAAA					1136
				355										

TTGTGCCAGC AGTTTTCTGA ATTTGAAAGA GTATTACTCT GGCTACTTCC	1186
TCAGAGAAGT AGCACTTAAT TTAACTTTT AAAAAAATAC TAACAAAATA	1236
CCAACACAGT AAGTACATAT TATTCTTCCT TGCAACTTTG AGCCTTGTCA	1286
AATGGGAGAA TGACTCTGTA GTAATCAGAT GTAAATTCCC AATGATTCT	1336
TATCTGCGGA ATTCCAGCTG AGCGCCGGTC GCTACCATTA CCAGTTGGTC	1386
TGGTGTGAC GACTCCTGGA GCCCGTCAGT ATCGGCG	1423

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 bases
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Other Nucleic Acid

- (A) DESCRIPTION: PCR primer α GT-1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GAATTCAAGC TTATGATCAC TATGCTTCAA

30

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 bases
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Other Nucleic Acid

- (A) DESCRIPTION: PCR primer α GT-2

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GAATTCCTGC AGTCAGACAT TATTCTAAC

29

What is claimed is:

1. An isolated nucleic acid molecule comprising:
 - (a) a sense sequence of contiguous nucleotides of SEQ ID NO:1, said sense sequence being unique to the porcine genome and of a length sufficient for use as a PCR primer or hybridization probe for the identification and/or isolation of the porcine $\alpha(1,3)$ galactosyl transferase gene; or
 - (b) an antisense sequence complementary to (a); or
 - (c) both (a) and (b).
2. The isolated nucleic acid molecule of Claim 1 wherein the sense sequence comprises at least 21 contiguous nucleotides of SEQ ID NO:1.
3. An isolated nucleic acid molecule comprising:
 - (a) a sense sequence of contiguous nucleotides of SEQ ID NO:2, said sense sequence being unique to the porcine genome and of a length sufficient for use as a PCR primer or hybridization probe for the identification and/or isolation of the porcine $\alpha(1,3)$ galactosyl transferase gene; or
 - (b) an antisense sequence complementary to (a); or
 - (c) both (a) and (b).
4. The isolated nucleic acid molecule of Claim 3 wherein the sense sequence comprises at least 21 contiguous nucleotides of SEQ ID NO:2.
5. A cloned porcine genomic DNA molecule comprising a sequence of nucleotides unique to the porcine genome, said DNA molecule hybridizing

specifically to the isolated nucleic acid molecule of Claim 1.

6. A cloned porcine genomic DNA molecule comprising a sequence of nucleotides unique to the porcine genome, said DNA molecule hybridizing specifically to the isolated nucleic acid molecule of Claim 3.

7. A cloned porcine genomic DNA molecule comprising a sequence of nucleotides unique to the porcine genome, said DNA molecule hybridizing specifically to a nucleic acid probe having the nucleotide sequence set forth in SEQ ID NO:1.

8. A cloned porcine genomic DNA molecule comprising a sequence of nucleotides unique to the porcine genome, said DNA molecule hybridizing specifically to a nucleic acid probe having the nucleotide sequence set forth in SEQ ID NO:2.

9. A method for blocking human anti-Gal α (1,3)Gal antibodies comprising changing the conformation of the antibody reactive site so as to reduce the affinity of the antibody for the Gal α (1,3)Gal epitope.

10. The method of Claim 9 wherein the conformation of the antibody reactive site is changed through the use of an anti-idiotypic antibody.

11. A mammalian cell comprising a copy of the isolated nucleic acid molecule of Claim 1, said copy not being present in the native cell.

12. The mammalian cell of Claim 11 wherein the cell does not produce a functional $\alpha(1,3)$ galactosyl transferase as a result of homologous recombination of said copy with the cell's genomic DNA.

13. A mammalian cell comprising a copy of the isolated nucleic acid molecule of Claim 3, said copy not being present in the native cell.

14. The mammalian cell of Claim 13 wherein the cell does not produce a functional $\alpha(1,3)$ galactosyl transferase as a result of homologous recombination of said copy with the cell's genomic DNA.

15. A mammalian cell comprising a copy of the cloned porcine genomic DNA molecule of Claim 5, said copy not being present in the native cell.

16. The mammalian cell of Claim 15 wherein the cell does not produce a functional $\alpha(1,3)$ galactosyl transferase as a result of homologous recombination of said copy with the cell's genomic DNA.

17. A mammalian cell comprising a copy of the cloned porcine genomic DNA molecule of Claim 6, said copy not being present in the native cell.

18. The mammalian cell of Claim 17 wherein the cell does not produce a functional $\alpha(1,3)$ galactosyl transferase as a result of homologous recombination of said copy with the cell's genomic DNA.

19. A mammalian cell comprising a copy of the cloned porcine genomic DNA molecule of Claim 7, said copy not being present in the native cell.

20. The mammalian cell of Claim 19 wherein the cell does not produce a functional $\alpha(1,3)$ galactosyl transferase as a result of homologous recombination of said copy with the cell's genomic DNA.

21. A mammalian cell comprising a copy of the cloned porcine genomic DNA molecule of Claim 8, said copy not being present in the native cell.

22. The mammalian cell of Claim 21 wherein the cell does not produce a functional $\alpha(1,3)$ galactosyl transferase as a result of homologous recombination of said copy with the cell's genomic DNA.



23. Clone pPGT-4 having deposit designation number AGAL N94/9030.

24. Clone pPGT-2 having deposit designation number AGAL N94/9029.

25. Clone λ PGT-g1 having deposit designation AGAL N94/9027.




26. Clone λ PGT-g5 having deposit designation number AGAL N94/9028.

1/5

FIGURE 1**A****B**

2/5

FIGURE 2



3/5

FIGURE 3





FIGURE 4



4/5

FIGURE 5






FIGURE 6




5/5

FIGURE 7



BEST AVAILABLE COPY

A. CLASSIFICATION OF SUBJECT MATTER Int. Cl. ⁵ C12N 15/54, C12N 9/10, C12N 5/10 According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) WPAT & CASM using keywords in electronic data base Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched AU Int. Cl. ⁵ : C12N 15/54, C12N 9/10 Electronic data base consulted during the international search (name of data base, and where practicable, search terms used) 1. STN: Subsequences VPSSNSASQSP and MNVKGRVLSMLL 2. WPAT, CASM & BIOT: Electronic data base terms: (porcine or pig) and [(Galactosyltransferase# or Galactosyl(w)transferase#) or (xeno(w)graft or xenograft or xenotransplant)]				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.		
P,X	Dabkowski <u>et al.</u> , "Characterisation of a cDNA clone encoding the P α 1,3 Galactosyltransferase: Implications for Xenotransplantation", in Transplantation Proceedings, Vol. 25(5), October 1993, page 2921	1-26		
P,X	Sandrin <u>et al.</u> , "Anti-pig IgM antibodies in human serum react predominantly with Gal (α 1-3) Gal epitopes", in Proc. Natl. Acad. Sci. USA, Vol. 90, December (1993) pp. 11391-5	1-26		
P,X	Sandrin <u>et al.</u> , "Studies on Human naturally occurring Antibodies to Pig Xenografts", in Transplantation Proceedings, Vol. 25(5), October 1993, pp. 2917-8.	9,10		
<div style="display: flex; justify-content: space-between;"> <div style="text-align: left;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. </div> <div style="text-align: left;"> <input checked="" type="checkbox"/> See patent family annex. </div> </div>				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top;"> <p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </td> <td style="width: 50%; vertical-align: top;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p> </td> </tr> </table>			<p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>
<p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>			
Date of the actual completion of the international search 30 May 1994 (30.05.94)		Date of mailing of the international search report 6 June 1994 (06.06.94)		
Name and mailing address of the ISA/AU AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No. (06) 2853929		Authorized officer  JANET PAGAN Telephone No. (06) 2832313		

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate of the relevant passages	Relevant to Claim No.
X	Joziase <u>et al.</u> , "Bovine α 1 \rightarrow 3-Galactosyltransferase: Isolation and characterization of a cDNA clone", in J. Biol. Chem., Vol. 264(24), 25 August 1989, pp. 14290-7	1-26
P,X	WO 93/16729 (Biotransplant Inc.) 2 September 1993 (02.09.93) (see entire document)	9,10
A	WO 91/12340 (The Regents of the University of Michigan) 22 August 1991 (22.08.91)	

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member	
WO	91/12340	CA EP	2075949 515536	JP	5504480
WO	93/16729	AU	37796/93		